Charles E. Cooley

Array ( [id] => 19840162 [patent_doc_number] => 12252531 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Methods of screening for high-affinity, isoform-selective TGFb1 inhibitors [patent_app_type] => utility [patent_app_number] => 17/258771 [patent_app_country] => US [patent_app_date] => 2019-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 78 [patent_figures_cnt] => 86 [patent_no_of_words] => 118399 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 293 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17258771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200143 [patent_doc_number] => 20210340238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => TGFss1 INHIBITORS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/258908 [patent_app_country] => US [patent_app_date] => 2019-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87149 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17258908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156176 [patent_doc_number] => 20210317227 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 17/259443 [patent_app_country] => US [patent_app_date] => 2019-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 97757 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17259443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16932461 [patent_doc_number] => 20210198350 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => USE OF A SCLEROSTIN ANTAGONIST [patent_app_type] => utility [patent_app_number] => 17/256572 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12286 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17256572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15267453 [patent_doc_number] => 20190382460 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => Modified FGF-21 Polypeptides and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/455990 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78827 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16455990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15960567 [patent_doc_number] => 20200164035 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => METHODS OF USING VARIANTS OF FGF19 POLYPEPTIDES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/453164 [patent_app_country] => US [patent_app_date] => 2019-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16453164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17080637 [patent_doc_number] => 20210275643 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO [patent_app_type] => utility [patent_app_number] => 17/252627 [patent_app_country] => US [patent_app_date] => 2019-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 297 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17252627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17177363 [patent_doc_number] => 11154592 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-26 [patent_title] => Method of treating Rett Syndrome (RTT) with ghrelin [patent_app_type] => utility [patent_app_number] => 16/437486 [patent_app_country] => US [patent_app_date] => 2019-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 21 [patent_no_of_words] => 5798 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16437486 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19638090 [patent_doc_number] => 12168691 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-17 [patent_title] => VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof [patent_app_type] => utility [patent_app_number] => 17/058414 [patent_app_country] => US [patent_app_date] => 2019-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 24 [patent_no_of_words] => 18598 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17058414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14864845 [patent_doc_number] => 20190282664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => METHODS FOR STIMULATION OF APPETITE AND INCREASE IN WEIGHT BY ADMINISTRATION OF ASPROSIN [patent_app_type] => utility [patent_app_number] => 16/424321 [patent_app_country] => US [patent_app_date] => 2019-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16424321 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839517 [patent_doc_number] => 20210147529 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => PHARMACEUTICAL COMPOSITION FOR SUPPRESSING ATRIAL FIBRILLATION HAVING AS ACTIVE INGREDIENT ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF [patent_app_type] => utility [patent_app_number] => 17/055406 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19120038 [patent_doc_number] => 11963999 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-23 [patent_title] => Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant FC fusion proteins [patent_app_type] => utility [patent_app_number] => 16/407813 [patent_app_country] => US [patent_app_date] => 2019-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 30 [patent_no_of_words] => 22720 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16407813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885452 [patent_doc_number] => 20210171647 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => FULLY HUMAN ANTIBODIES AGAINST OX40, METHOD FOR PREPARING THE SAME, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/054700 [patent_app_country] => US [patent_app_date] => 2019-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28164 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16807869 [patent_doc_number] => 20210130422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => Novel Fusion Protein, and Pharmaceutical Composition For Preventing Or Treating Cancer, Containing Same [patent_app_type] => utility [patent_app_number] => 17/050816 [patent_app_country] => US [patent_app_date] => 2019-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17050816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715633 [patent_doc_number] => 20190248880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => CARTILAGE TARGETING AGENTS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 16/391101 [patent_app_country] => US [patent_app_date] => 2019-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16391101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16991841 [patent_doc_number] => 20210230261 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => BUFFERED FORMULATIONS OF BEVACIZUMAB FOR USE OF TREATING DISEASES [patent_app_type] => utility [patent_app_number] => 17/048107 [patent_app_country] => US [patent_app_date] => 2019-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17048107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17922846 [patent_doc_number] => 11466079 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => C-terminal antibody variants [patent_app_type] => utility [patent_app_number] => 16/971590 [patent_app_country] => US [patent_app_date] => 2019-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 15699 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16971590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836089 [patent_doc_number] => 20190276445 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => BLOCKERS OF THE GROWTH HORMONE RECEPTOR IN DISEASE PREVENTION AND TREATMENT [patent_app_type] => utility [patent_app_number] => 16/366662 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16366662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17308341 [patent_doc_number] => 11209444 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => Treatment for age-related macular degeneration (AMD) and pathogenic ocular neovascularization [patent_app_type] => utility [patent_app_number] => 16/363886 [patent_app_country] => US [patent_app_date] => 2019-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 28 [patent_no_of_words] => 23457 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16363886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18302069 [patent_doc_number] => 11623960 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-11 [patent_title] => Dual-function antibodies targeting VEGFR2 and VEGFR3 [patent_app_type] => utility [patent_app_number] => 16/982361 [patent_app_country] => US [patent_app_date] => 2019-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9912 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16982361 [rel_patent_id] =>[rel_patent_doc_number] =>)